Hepatic Hippo signaling inhibits development of hepatocellular carcinoma

키워드

참고문헌 (93)

1. El-Serag HB, "Hepatocellular carcinoma", N Engl J Med, 365, pp.1118~1127 (2011)
2. Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)
3. Farazi PA, "Hepatocellular carcinoma pathogenesis : from genes to environment", Nat Rev Cancer, 6, pp.674~687 (2006)
4. Hanahan D, "Hallmarks of cancer : the next generation", Cell, 144, pp.646~674 (2011)
5. Forner A, "Hepatocellular carcinoma", Lancet, 379, pp.1245~1255 (2012)
6. Yu H, "Revisiting STAT3 signalling in cancer : new and unexpected biological functions", Nat Rev Cancer, 14, pp.736~746 (2014)
7. Miyajima A, "Stem", progenitor cells in liver development, homeostasis, regeneration, and reprogramming, 2014, pp.14, 561~574
8. Tahmasebi Birgani M, "Tumor microenvironment, a paradigm in hepatocellular carcinoma progression and therapy", Int J Mol Sci, 18, pp.405~ (2017)
9. Zheng Y, "The hippo signaling pathway in development and disease", Dev Cell, 50, pp.264~282 (2019)
10. Yu FX, "Hippo pathway in organ size control, tissue homeostasis, and cancer", Cell, 163, pp.811~828 (2015)
11. Pan D, "The hippo signaling pathway in development and cancer", Dev Cell, 19, pp.491~505 (2010)
12. Aragona M, "A mechanical checkpoint controls multicellular growth through YAP", TAZ regulation by actin-processing factors, 2013, pp.154, 1047~1059
13. Dupont S, "Role of YAP", TAZ in mechanotransduction, 2011, pp.474, 179~183
14. Yu FX, "Regulation of the hippo-YAP pathway by G-protein-coupled receptor signaling", Cell, 150, pp.780~791 (2012)
15. Chen R, "STRIPAK integrates upstream signals to initiate the hippo kinase cascade", Nat Cell Biol, 21, pp.1565~1577 (2019)
16. Dong J, "Elucidation of a universal size-control mechanism in Drosophila and mammals", Cell, 130, pp.1120~1133 (2007)
17. Zhao B, "Inactivation of YAP oncoprotein by the hippo pathway is involved in cell contact inhibition and tissue growth control", Genes Dev, 21, pp.2747~2761 (2007)
18. Zhao B, "A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP)", Genes Dev, 24, pp.72~85 (2010)
19. Kwon Y, "The hippo signaling pathway interactome", Science, 342, pp.737~740 (2013)
20. Callus BA, "Association of mammalian sterile twenty kinases, Mst1 and Mst2, with hSalvador via C-terminal coiled-coil domains, leads to its stabilization and phosphorylation", FEBS J, 273, pp.4264~4276 (2006)
21. Praskova M, "MOBKL1A", MOBKL1B phosphorylation by MST1 and MST2 inhibits cell proliferation, 2008, pp.18, 311~321
22. Tapon N, "Salvador promotes both cell cycle exit and apoptosis in drosophila and is mutated in human cancer cell lines", Cell, 110, pp.467~478 (2002)
23. Wu S, "Hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts", Cell, 114, pp.445~456 (2003)
24. Hao Y, "Tumor suppressor LATS1 is a negative regulator of oncogene YAP", J Biol Chem, 283, pp.5496~5509 (2008)
25. Liu CY, "The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCFβ-TrCP E3 ligase", J Biol Chem, 285, pp.37159~37169 (2010)
26. Lai D, "Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF", Cancer Res, 71, pp.2728~2738 (2011)
27. Zhao B, "TEAD mediates YAP-dependent gene induction and growth control", Genes Dev, 22, pp.1962~1971 (2008)
28. Vassilev A, "TEAD", TEF transcription factors utilize the activation domain of YAP65, a src, Genes Dev, pp.2001, 15[DOI]
29. Song H, "Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression", Proc Natl Acad Sci U S A, 107, pp.1431~1436 (2010)
30. Zhou D, "Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene", Cancer Cell, 16, pp.425~438 (2009)
31. Lu L, "Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver", Proc Natl Acad Sci U S A, 107, pp.1437~1442 (2010)
32. Zender L, "Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach", Cell, 125, pp.1253~1267 (2006)
33. Camargo FD, "YAP1 increases organ size and expands undifferentiated progenitor cells", Curr Biol, 17, pp.2054~2060 (2007)
34. Yimlamai D, "Hippo pathway activity influences liver cell fate", Cell, 157, pp.1324~1338 (2014)
35. Nishio M, "Cancer susceptibility and embryonic lethality in Mob1a", 1b double-mutant mice, 2012, pp.122, 4505~4518
36. Nishio M, "Dysregulated YAP1", TAZ and TGF-β signaling mediate hepatocarcinogenesis in Mob1a, Proc Natl Acad Sci U S A, pp.2016, 113[DOI]
37. Zhang N, "The Merlin", NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals, 2010, pp.19, 27~38
38. Benhamouche S, "Nf2", Merlin controls progenitor homeostasis and tumorigenesis in the liver, 2010, pp.24, 1718~1730
39. Yin F, "Spatial organization of hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin", NF2, 2013, pp.154, 1342~1355
40. Khan SA, "Cholangiocarcinoma", Lancet, 366, pp.1303~1314 (2005)
41. Guo Y, "Functional and clinical evidence that TAZ is a candidate oncogene in hepatocellular carcinoma", J Cell Biochem, 116, pp.2465~2475 (2015)
42. Xu MZ, "Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma", Cancer, 115, pp.4576~4585 (2009)
43. Sohn BH, "Inactivation of hippo pathway is significantly associated with poor prognosis in hepatocellular carcinoma", Clin Cancer Res, 22, pp.1256~1264 (2016)
44. Tao J, "Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice", Gastroenterology, 147, pp.690~701 (2014)
45. Weiler SME, "Induction of chromosome instability by activation of yes-associated protein and forkhead box M1 in liver cancer", Gastroenterology, 152, pp.2037~2051.e22 (2017)
46. Lee KP, "The hipposalvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis", Proc Natl Acad Sci U S A, 107, pp.8248~8253 (2010)
47. Hermann A, "WW and C2 domain-containing proteins regulate hepatic cell differentiation and tumorigenesis through the hippo signaling pathway", Hepatology, 67, pp.1546~1559 (2018)
48. Chen Q, "Homeostatic control of Hippo signaling activity revealed by an endogenous activating mutation in YAP", Genes Dev, 29, pp.1285~1297 (2015)
49. Yi J, "Large tumor suppressor homologs 1 and 2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ", Hepatology, 64, pp.1757~1772 (2016)
50. Kim W, "Hepatic hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma", Gut, 67, pp.1692~1703 (2018)
51. Lee DH, "LATSYAP", TAZ controls lineage specification by regulating TGFβ signaling and Hnf4α expression during liver development, 2016, pp.7, 11961~
52. Van Haele M, "YAP and TAZ heterogeneity in primary liver cancer : an analysis of its prognostic and diagnostic role", Int J Mol Sci, 20, pp.638~ (2019)
53. Li H, "Deregulation of hippo kinase signalling in human hepatic malignancies", Liver Int, 32, pp.38~47 (2012)
54. Fitamant J, "YAP inhibition restores hepatocyte differentiation in advanced hcc, leading to tumor regression", Cell Rep, 10, pp.1692~1707 (2015)
55. Zhang S, "Role of the transcriptional coactivators YAP", TAZ in liver cancer, 2019, pp.61, 64~71
56. Kim W, "Hippo signaling interactions with Wnt", β-catenin and Notch signaling repress liver tumorigenesis, 2017, pp.127, 137~152
57. Kim W, "Hippo signaling is intrinsically regulated during cell cycle progression by APC", CCdh1, 2019, pp.116, 9423~9432
58. Cho YS, "CDK7 regulates organ size and tumor growth by safeguarding the hippo pathway effector Yki", Yap, Genes Dev, pp.2020, 34[DOI]
59. de La Coste A, "Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas", Proc Natl Acad Sci U S A, 95, pp.8847~8851 (1998)
60. He G, "Hepatocyte IKKbeta", NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation, 2010, pp.17, 286~297
61. He G, "NF-κB and STAT3-key players in liver inflammation and cancer", Cell Res, 21, pp.159~168 (2011)
62. Villanueva A, "Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice", Gastroenterology, 143, pp.1660~1669.e7 (2012)
63. Zong Y, "Notch signaling controls liver development by regulating biliary differentiation", Development, 136, pp.1727~1739 (2009)
64. Geisler F, "Emerging roles of Notch signaling in liver disease", Hepatology, 61, pp.382~392 (2015)
65. Tschaharganeh DF, "Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma", Gastroenterology, 144, pp.1530~1542.e12 (2013)
66. Wu H, "The Ets transcription factor GABP is a component of the hippo pathway essential for growth and antioxidant defense", Cell Rep, 3, pp.1663~1677 (2013)
67. Zhang S, "Hippo signaling suppresses cell ploidy and tumorigenesis through Skp2", Cancer Cell, 31, pp.669~684.e7 (2017)
68. Balkwill F, "Inflammation and cancer : back to Virchow?", Lancet, 357, pp.539~545 (2001)
69. Block TM, "Molecular viral oncology of hepatocellular carcinoma", Oncogene, 22, pp.5093~5107 (2003)
70. Canavese M, "Hepatitis C virus drives the pathogenesis of hepatocellular carcinoma : from immune evasion to carcinogenesis", Clin Transl Immunology, 5, pp.e101~ (2016)
71. Nakamoto Y, "Immune pathogenesis of hepatocellular carcinoma", J Exp Med, 188, pp.341~350 (1998)
72. Wynn TA, "Macrophage biology in development, homeostasis and disease", Nature, 496, pp.445~455 (2013)
73. Noy R, "Tumor-associated macrophages : from mechanisms to therapy", Immunity, 41, pp.49~61 (2014)
74. Guo X, "Single tumorinitiating cells evade immune clearance by recruiting type II macrophages", Genes Dev, 31, pp.247~259 (2017)
75. Wang X, "Hepatocyte TAZ", WWTR1 promotes inflammation and fibrosis in nonalcoholic steatohepatitis, 2016, pp.24, 848~862
76. Janse van Rensburg HJ, "The hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1", Cancer Res, 78, pp.1457~1470 (2018)
77. Feng J, "Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells", Oncogene, 36, pp.5829~5839 (2017)
78. Finn RS, "Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma", N Engl J Med, 382, pp.1894~1905 (2020)
79. Moroishi T, "The hippo pathway kinases LATS1", 2 suppress cancer immunity, 2016, pp.167, 1525~1539.e17
80. Abdollahpour H, "The phenotype of human STK4 deficiency", Blood, 119, pp.3450~3457 (2012)
81. Geng J, "The transcriptional coactivator TAZ regulates reciprocal differentiation of TH17 cells and Treg cells", Nat Immunol, 18, pp.800~812 (2017)
82. Ni X, "YAP is essential for treg-mediated suppression of antitumor immunity", Cancer Discov, 8, pp.1026~1043 (2018)
83. Fan Y, "YAP-1 promotes tregs differentiation in hepatocellular carcinoma by enhancing TGFBR2 transcription", Cell Physiol Biochem, 41, pp.1189~1198 (2017)
84. Koo JH, "Interplay between YAP", TAZ and metabolism, 2018, pp.28, 196~206
85. Hagenbeek TJ, "The hippo pathway effector TAZ induces TEAD-dependent liver inflammation and tumors", Sci Signal, 11, pp.eaaj1757~ (2018)
86. Ye J, "JCAD promotes progression of nonalcoholic steatohepatitis to liver cancer by inhibiting LATS2 kinase activity", Cancer Res, 77, pp.5287~5300 (2017)
87. Enzo E, "Aerobic glycolysis tunes YAP", TAZ transcriptional activity, 2015, pp.34, 1349~1370
88. Mo JS, "Cellular energy stress induces AMPK-mediated regulation of YAP and the hippo pathway", Nat Cell Biol, 17, pp.500~510 (2015)
89. Huntoon CJ, "Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway", Cancer Res, 70, pp.8642~8650 (2010)
90. Zhang X, "Yes-associated protein(YAP)binds to HIF-1α and sustains HIF-1α protein stability to promote hepatocellular carcinoma cell glycolysis under hypoxic stress", J Exp Clin Cancer Res, 37, pp.216~ (2018)
91. Chen R, "High mobility group protein B1 controls liver cancer initiation through yes-associated protein-dependent aerobic glycolysis", Hepatology, 67, pp.1823~1841 (2018)
92. Sorrentino G, "Metabolic control of YAP and TAZ by the mevalonate pathway", Nat Cell Biol, 16, pp.357~366 (2014)
93. Higashi T, "Statin attenuates cell proliferative ability via TAZ(WWTR1)in hepatocellular carcinoma", Med Oncol, 33, pp.123~ (2016)

관련 논문AI추천